BAIJIN LIFE SCI (01466) Subsidiary Signs Strategic Cooperation Framework Agreement with Guhuan Medical

Stock News

Dec 01

BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Co., Ltd. (Guhuan Medical). Under the agreement, Beijing Baijin will invest in Guhuan Medical through equity subscription, aiming to establish direct sales channels for the Group's branded medical products. Additionally, Mr. Liang Liang is expected to be appointed as the Director of the Group's Medical Business Division, responsible for medical product expansion.

The cooperation framework agreement will expire on December 31, 2026, and either party may terminate it with 10 days' prior notice.

Shanghai Guhuan Medical Equipment Co., Ltd. has over a decade of experience in the medical product supply chain, with strong partnerships across upstream and downstream suppliers, and holds direct or indirect stakes in more than 30 medical aesthetic institutions. Mr. Liang Liang brings extensive expertise in the medical aesthetics industry, covering supply chain management, medical institution operations, and investment management.

The Board believes that this agreement will support the Group in enhancing its medical product market ecosystem—from R&D to proprietary sales channels—while steadily expanding revenue streams.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102760890"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102760890\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102760890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102760890","market":"other","top_or_hot":-1,"title":"BAIJIN LIFE SCI (01466) Subsidiary Signs Strategic Cooperation Framework Agreement with Guhuan Medical","media":"Stock News","content":"<p>BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Co., Ltd. (Guhuan Medical). Under the agreement, Beijing Baijin will invest in Guhuan Medical through equity subscription, aiming to establish direct sales channels for the Group's branded medical products. Additionally, Mr. Liang Liang is expected to be appointed as the Director of the Group's Medical Business Division, responsible for medical product expansion.</p>\n<p>The cooperation framework agreement will expire on December 31, 2026, and either party may terminate it with 10 days' prior notice.</p>\n<p>Shanghai Guhuan Medical Equipment Co., Ltd. has over a decade of experience in the medical product supply chain, with strong partnerships across upstream and downstream suppliers, and holds direct or indirect stakes in more than 30 medical aesthetic institutions. Mr. Liang Liang brings extensive expertise in the medical aesthetics industry, covering supply chain management, medical institution operations, and investment management.</p>\n<p>The Board believes that this agreement will support the Group in enhancing its medical product market ecosystem—from R&D to proprietary sales channels—while steadily expanding revenue streams.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIJIN LIFE SCI (01466) Subsidiary Signs Strategic Cooperation Framework Agreement with Guhuan Medical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIJIN LIFE SCI (01466) Subsidiary Signs Strategic Cooperation Framework Agreement with Guhuan Medical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Co., Ltd. (Guhuan Medical). Under the agreement, Beijing Baijin will invest in Guhuan Medical through equity subscription, aiming to establish direct sales channels for the Group's branded medical products. Additionally, Mr. Liang Liang is expected to be appointed as the Director of the Group's Medical Business Division, responsible for medical product expansion.</p>\n<p>The cooperation framework agreement will expire on December 31, 2026, and either party may terminate it with 10 days' prior notice.</p>\n<p>Shanghai Guhuan Medical Equipment Co., Ltd. has over a decade of experience in the medical product supply chain, with strong partnerships across upstream and downstream suppliers, and holds direct or indirect stakes in more than 30 medical aesthetic institutions. Mr. Liang Liang brings extensive expertise in the medical aesthetics industry, covering supply chain management, medical institution operations, and investment management.</p>\n<p>The Board believes that this agreement will support the Group in enhancing its medical product market ecosystem—from R&D to proprietary sales channels—while steadily expanding revenue streams.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01466","symbol_name":"佰金生命-八千","start_time":0,"source_url":"","article_id":"1102760890","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102760890","pubTimestamp":1764580698,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","01466":"佰金生命-八千","BK1227":"服装、服饰与奢侈品"},"translate_title":"百金生命SCI(01466)附属公司与谷环医疗签署战略合作框架协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"01466":1},"content_text":"BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Co., Ltd. (Guhuan Medical). Under the agreement, Beijing Baijin will invest in Guhuan Medical through equity subscription, aiming to establish direct sales channels for the Group's branded medical products. Additionally, Mr. Liang Liang is expected to be appointed as the Director of the Group's Medical Business Division, responsible for medical product expansion.\nThe cooperation framework agreement will expire on December 31, 2026, and either party may terminate it with 10 days' prior notice.\nShanghai Guhuan Medical Equipment Co., Ltd. has over a decade of experience in the medical product supply chain, with strong partnerships across upstream and downstream suppliers, and holds direct or indirect stakes in more than 30 medical aesthetic institutions. Mr. Liang Liang brings extensive expertise in the medical aesthetics industry, covering supply chain management, medical institution operations, and investment management.\nThe Board believes that this agreement will support the Group in enhancing its medical product market ecosystem—from R&D to proprietary sales channels—while steadily expanding revenue streams.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}